Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
19.3M
-
Number of holders
-
114
-
Total 13F shares, excl. options
-
133M
-
Shares change
-
+398K
-
Total reported value, excl. options
-
$194M
-
Value change
-
-$1.42M
-
Put/Call ratio
-
2.88
-
Number of buys
-
47
-
Number of sells
-
-66
-
Price
-
$1.45
Significant Holders of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL) as of Q2 2024
139 filings reported holding LYEL - Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share as of Q2 2024.
Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL) has 114 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 133M shares
.
Largest 10 shareholders include MWG Management Ltd. (20.2M shares), Orland Properties Ltd (15.1M shares), BlackRock Inc. (13.5M shares), VANGUARD GROUP INC (13.4M shares), Foresite Capital Management IV, LLC (8.33M shares), PRICE T ROWE ASSOCIATES INC /MD/ (7.87M shares), WuXi AppTec Co., Ltd. (7.68M shares), ORBIMED ADVISORS LLC (6.41M shares), Alphabet Inc. (5.87M shares), and GEODE CAPITAL MANAGEMENT, LLC (4.01M shares).
This table shows the top 114 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.